Business
Nanalysis Appoints Dr. René Lenggenhager to Board of Directors
Nanalysis Appoints Dr. René Lenggenhager to Board of Directors Canada News...
About this update from Nanalysis Scientific Corp
[{"type":"text","content":"\n \n \n \n Nanalysis Appoints Dr. René Lenggenhager to Board of Directors\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n CALGARY, AB\n \n ,\n \n Dec. 15, 2021\n \n /CNW/ -\n \n \n Nanalysis Scientific Corp.\n \n \n \n \n (\"\n \n Nanalysis\" or the \"Company\")\n \n ,\n \n TSXV:NSCI\n \n , OTCQX:NSCIF, FRA:1N1) is pleased to announce that, effective\n \n January 1, 2022\n \n , Dr. René Lenggenhager, is joining its Board of Directors. Dr. Lenggenhager is an experienced public company executive and board member with a successful career in leading global technology companies. In addition, the Company is pleased to announce that Dr. Lenggenhager is investing in Nanalysis via non-brokered private placement of 150,000 common shares of the Company (\"Common Shares\") at a price of\n \n $1.35\n \n per share for aggregate gross proceeds of\n \n $202,500\n \n (the \"Offering\").\n \n \n \n \n \n \n \n \n \n Dr. Lenggenhager brings to Nanalysis a diverse set of experiences and capabilities over a 37 year career in advanced industrial technology.  He has a background of continuously innovating technology components and systems, with a focus on high-precision measuring, testing and automation equipment. His experience includes over 20 years of management and development, with full P&L responsibility, of globally active, publicly listed, innovative technology companies: Comet Group (COTN), Bruker BioSpin (BRKR), Mettler-Toledo (MTD) and Siemens Building Technologies. During his career he defined and implemented new product strategies for low- to high-field Nuclear Magnetic Resonance (NMR) products, and consolidated all service activities into one service division. Dr. Lenggenhager also deployed a global supply chain management and an outsourcing strategy. Additionally, he realigned the marketing and sales management, transforming from a technology to a market-oriented company. He has developed new product portfolio strategies, based on platforms, modularization and production with lean manufacturing principles...